If you or someone you love has been harmed by
Phenylpropanolamine (PPA), you may be entitled to
compensation. PPA Phenylpropanolamine is an ingredient
in many over-the-counter (OTC) and prescription diet
drugs, as well as nasal decongestants and cough
medicine. PPA has been linked to dangerous side effects
such as hemorrhagic strokes that can afflict users
within three days of taking the medication.
Martinez, Manglardi, Diez-Arguelles & Tejedor, P.A. knows the dangers of PPA and other unsafe
drugs. Since 1988, Florida’s personal injury victims
have turned to our attorneys for help in personal injury
and dangerous drug cases, as well as wrongful death,
motor vehicle crashes, product liability, medical
malpractice, nursing home abuse, insurance contract
disputes and theme park negligence claims. We have
helped Floridians receive millions of dollars in
favorable verdicts and settlements. Our team of
professionals includes nurses, doctors, engineers and
other experts who are supported by leading technology
that enables us to keep in touch with the legal
community, legislative developments and our clients. If
you or someone you know has suffered adverse effects
from the use of PPA, you’ll need an attorney with the
experience and resources to help you stand up to the
giant drug manufacturers and insurance companies. We
encourage you to contact our
office today to discuss your situation. The consultation
is complimentary.
PPA has been available for at least
53 years, with as many as 400 over-the-counter (OTC)
products and prescription drugs containing PPA as an
active ingredient. Phenylpropanolamine is used in OTC
drugs as a nasal decongestant and in weight control
products to regulate appetite. You may recognize popular
name brands that contain Phenylpropanolamine including
Dexatrim, Acutrim, Alka-Seltzer, Bayer Cold, Robitussin,
Comtrex and Tavist D. If you are a consumer, check all
of the ingredients list on the package to ensure you
know exactly what you are taking.
In 2000, the Food
and Drug Administration (FDA) officially acted to have
Phenylpropanolamine removed from the market as a result
of a Yale study that concluded that women taking PPA-related
products were at a higher risk of hemorrhagic stroke
(bleeding into the brain or into tissue surrounding the
brain). While the study found that women are especially
vulnerable to hemorrhagic stroke, the FDA warned that
men may also in danger. The FDA requested that companies
that market drugs containing PPA voluntarily discontinue
marketing the pharmaceutical and advised consumers to
use an alternative drug. Alternatives for decongestion
include long acting nasal decongestant sprays that
contain oxymetolazine. In fact, it has been found that
using nasal sprays that contain oxymetolazine may be
more effect while producing less side effects than PPA
products. For those looking for help losing weight, all
effective appetite suppressants are stimulants that can
raise blood pressure. While PPA diet products may
produce short term weight loss, the only successful diet
for the long term is eating sensibly and exercising.
A
drug maker is held liable if they fail to manufacture a
safe product or are negligent in their responsibility to
design, manufacture, inspect, and label a product
appropriately. Proving negligence in pharmaceutical and
product liability claims is complicated. At Martinez, Manglardi, Diez-Arguelles & Tejedor, P.A., we speak for the victim. We have the
experience and resources to take on giant pharmaceutical
companies and insurance bureaucracies. Over $100 million
in verdicts and settlements demonstrates our ability to
effectively represent clients in a wide range of cases.
Contact Martinez, Manglardi, Diez-Arguelles & Tejedor, P.A.
today to learn more about how we may be able to help you
receive compensation for pain, lost wages, medical bills
and other damages. We offer free consultations in your
home, at the hospital or in our offices. There are no
fees or costs unless you win. Contact us today in
Orlando at (407) 381-4123, or in Kissimmee, (407)
846-2240 or via our online contact
form.
Phenylpropanolamine PPA in the News
Drug Enforcement Administration’s
(DEA)
Chemical Industry Conference 2004 (Sept. 14, 2004)
Of particular interest was the proposed rule on security
requirements for handlers of pseudoephedrine, ephedrine,
and phenylpropanolamine. DEA is proposing that the
security required to handle ephedrine, pseudoephedrine,
and phenylpropanolamine be enhanced to the level that is
required for Schedule III – V controlled substances.